Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Houston, Texas 77055


Purpose:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Antineoplastons are naturally occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells. It is not yet known whether giving antineoplastons with chemotherapy is more effective than chemotherapy alone in treating women with refractory breast cancer. PURPOSE: This randomized phase II trial is studying methotrexate alone to see how well it works campared to methotrexate and antineoplaston therapy in treating postmenopausal women with advanced refractory breast cancer.


Study summary:

OBJECTIVES: - Compare the antitumor activity of antineoplaston A10 with methotrexate vs methotrexate alone, in terms of objective tumor response, in women with advanced breast cancer. - Compare the adverse effects of and tolerance to these regimens in these patients. OUTLINE: This is a randomized study. - Arm I: Patients receive gradually escalating doses of oral antineoplaston A10 capsules 7 times daily until the maximum tolerated dose is reached, followed by oral methotrexate capsules 2 to 3 times per day in five days on and five days off courses. Treatment continues in the absence of disease progression or unacceptable toxicity. - Arm II: Patients receive oral methotrexate alone on the same schedule as in arm I. Tumors are measured every 4 months for 2 years, every 6 months for years 3 and 4, and then annually for years 5 and 6. PROJECTED ACCRUAL: A total of 30-70 patients will be accrued for this study within at least 12 months.


Criteria:

DISEASE CHARACTERISTICS: - Histologically confirmed advanced breast cancer that is refractory or unlikely to respond to hormonal therapy AND failed at least 1 prior chemotherapy regimen - Symptomatic lymphangitic pulmonary dissemination allowed - Extensive visceral metastasis allowed - Patients who are refractory or who have failed to respond after at least 8 weeks of methotrexate or a methotrexate-containing regimen are not eligible - Measurable disease - No bone metastases - Hormone receptor status: - Estrogen receptor negative PATIENT CHARACTERISTICS: Age: - Postmenopausal Sex: - Female Menopausal status: - Postmenopausal Performance status: - Karnofsky 60-100% Life expectancy: - At least 3 months Hematopoietic: - WBC at least 3,000/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin no greater than 2.5 mg/dL - SGOT no greater than 2 times normal - Blood ammonia normal - No hepatic failure Renal: - BUN less than 60 mg/dL - Creatinine no greater than 2.5 mg/dL - Creatinine clearance greater than 60 mL/min - No chronic renal failure Cardiovascular: - No severe heart disease Pulmonary: - No severe lung disease Other: - No serious active infections or fever - No other concurrent serious disease - No prior or concurrent secondary malignancies within the past 2 years - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 4 weeks since prior immunotherapy and recovered - No concurrent biologic therapy for metastatic breast cancer Chemotherapy: - See Disease Characteristics - At least 4 weeks since prior cytotoxic chemotherapy and recovered - No other concurrent chemotherapy for metastatic breast cancer Endocrine therapy: - See Disease Characteristics - At least 4 weeks since prior hormonal therapy and recovered - No concurrent hormonal therapy for metastatic breast cancer Radiotherapy: - At least 4 weeks since prior radiotherapy and recovered - No concurrent radiotherapy for metastatic breast cancer Surgery: - Not specified Other: - At least 4 weeks since prior participation in experimental clinical trials - No prior antineoplaston A10 therapy - No other concurrent treatment for metastatic breast cancer - No concurrent salicylates, nonsteroidal anti-inflammatory drugs, phenylbutazone, phenytoin, and sulfonamides


NCT ID:

NCT00003536


Primary Contact:

Study Chair
Stanislaw R. Burzynski, MD, PhD
Burzynski Research Institute


Backup Contact:

N/A


Location Contact:

Houston, Texas 77055
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 19, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.